Literature DB >> 15648956

MS-209 Schering.

Jacques Robert1.   

Abstract

MS-209, a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated protein-1, is under development by Schering for the potential treatment of multidrug resistant tumors. By March 2003, phase II trials in breast cancer and non-small-cell lung cancer had been initiated.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15648956

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

1.  Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.

Authors:  Ji Na Kong; Qian He; Guanghu Wang; Somsankar Dasgupta; Michael B Dinkins; Gu Zhu; Austin Kim; Stefka Spassieva; Erhard Bieberich
Journal:  Int J Cancer       Date:  2015-04-27       Impact factor: 7.396

Review 2.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

Review 3.  Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.

Authors:  M Mimeault; R Hauke; S K Batra
Journal:  Clin Pharmacol Ther       Date:  2007-09-05       Impact factor: 6.875

4.  Host sphingomyelin increases West Nile virus infection in vivo.

Authors:  Miguel A Martín-Acebes; Enrique Gabandé-Rodríguez; Ana M García-Cabrero; Marina P Sánchez; María Dolores Ledesma; Francisco Sobrino; Juan-Carlos Saiz
Journal:  J Lipid Res       Date:  2016-01-13       Impact factor: 5.922
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.